Zogenix to Participate in the Global Mizuho Investor Conference 2018

EMERYVILLE, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. ZGNX, a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will conduct investor meetings at the Global Mizuho Investor Conference 2018, taking place December 3-4, 2018, at the Lotte New York Palace Hotel in New York City.  The Company's meetings at the conference will be held on December 4.

About Zogenix
Zogenix ZGNX is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options, but face a critical need. For more information, visit www.zogenix.com.

CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Media: David Polk
Senior Media Relations Strategist, Syneos Health
310-309-1029 | david.polk@syneoshealth.com